Oncolytic Virus In Vivo Preclinical Study Services
The in vivo preclinical study of oncolytic viruses represents a pivotal step in ensuring their safe and effective application in clinical treatment. It furnishes crucial theoretical and experimental underpinnings for the design and execution of clinical trials. This, in turn, accelerates the development trajectory of oncolytic virus-based drugs and enhances the success rate of clinical translation.
In vivo preclinical studies are crucial for oncolytic viruses, covering multiple vital aspects. Safety assessment involves conducting toxicological studies in animal models to observe acute/chronic toxicity and histopathological changes in tissues/organs, evaluating immunogenicity to predict human immune adverse reactions, and defining the safe dose range. In pharmacokinetics and pharmacodynamics research, virus distribution, metabolism parameters, and anti-tumor mechanisms are determined, and pharmacodynamic indices are established. Finally, based on these results, the maximum tolerated and minimum effective doses are set, the dosing regimen is optimized, and patient selection and stratification in clinical trials are guided, enabling oncolytic viruses to be safely and effectively applied clinically.
Creative Biolabs has devised diverse preclinical in vivo testing methods tailored to distinct oncolytic virus development scenarios. Both immunocompetent and immunosuppressed mice and non-human primate models are suitable for validating the toxicity, efficacy, and biodistribution of oncolytic viruses. Our experienced scientists will assist you in developing the optimal testing protocols for customized oncolytic virotherapy. The in vivo preclinical efficacy and toxicity data generated in our good laboratory practice (GLP)-compliant laboratories are appropriate for investigational new drug (IND) submissions. Our seasoned scientists will assist you in formulating the optimal testing protocols for customized oncolytic viral therapies.
Featured Oncolytic Virus Preclinical Study Categories
- Animal Models for Oncolytic Virus Study
- Oncolytic Virus Immunogenicity Study
- Oncolytic Virus Biodistribution Study
- Oncolytic Virus Efficacy Study
- Oncolytic Virus Toxicology Study
Reference
- Johnson, Ben William, Ken Takahashi, and Yuen Yee Cheng. "Preclinical models and resources to facilitate basic science research on malignant mesothelioma–a review." Frontiers in Oncology 11 (2021): 748444. Distributed under Open Access license CC BY 4.0, part of the image is taken and reassembled.